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Key points	
● We have developed a targeted sequencing platform covering 63 genes 
linked to heritable bleeding, thrombotic and platelet disorders. 	
● The ThromboGenomics platform provides a sensitive genetic test to 
obtain molecular diagnoses in patients with a suspected etiology.		
ABSTRACT	
Inherited bleeding, thrombotic and platelet disorders (BPDs) are diseases 
affecting approximately 300 individuals per million births. With the exception 
of haemophilia and von Willebrand disease patients, a molecular analysis for 
patients with a BPD is often unavailable. Many specialised tests are usually 
required to reach a putative diagnosis and they are typically performed in a 
step-wise manner to control costs. This approach causes delays and a 
conclusive molecular diagnosis is often never reached which can compromise 
treatment and impede rapid identification of affected relatives. To address this 
unmet diagnostic need, we designed a high-throughput sequencing (HTS) 
platform targeting 63 genes relevant for BPDs. The platform can call single 
nucleotide variants (SNVs), short insertions/deletions (indels) and large copy 
number variants (CNVs), though not inversions, which are subjected to 
automated filtering for diagnostic prioritization, resulting in an average of 5.34 
candidate variants per individual. We sequenced 159 and 137 samples 
respectively from cases with and without previously known causal variants. 
Among the latter group, 61 cases had clinical and laboratory phenotypes 
indicative of a particular molecular etiology while the remainder had an a priori 
highly uncertain etiology. All previously detected variants were recapitulated 
and, when the etiology was suspected but unknown or uncertain, a molecular 
diagnosis was reached in 56 of 61 and only eight of 76 cases, respectively. 
The latter category highlights the need for further research into novel causes 
of BPDs. The ThromboGenomics platform thus provides an affordable DNA-
based test to diagnose patients suspected of having a known inherited BPD.		
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INTRODUCTION	
HTS of genomic DNA is being introduced into clinical practice1 and broadly 
falls into two categories: whole genome sequencing (WGS)2 and targeted 
sequencing of pre-specified regions of the genome by means of probe-based 
capture. These regions may include all exons (whole exome sequencing 
(WES)) and be sequenced to moderate depth or they may comprise a much 
smaller fraction of the genome and be sequenced to high depth3.  Capture 
probes targeting regions that have been widely studied and implicated in a 
group of rare heritable disorders can turn HTS into a valuable tool for their 
affordable diagnosis.		
In this work, we focus on the diagnosis of rare heritable BPDs. Previously, we 
have defined a BPD case as a patient having abnormal platelet count, 
volume, morphology or function, or with a tendency to bleed abnormally4. The 
abnormal phenotypes must furthermore be judged to have a genetic basis, 
thereby ruling out diseases that may have been acquired or thought to be 
caused by exposure to known environmental risk factors. For the purposes of 
this paper, we also include patients with an abnormal tendency to thrombus 
formation in our definition. Currently 90% of BPD cases who do not have 
hemophilia5 or von Willebrand disease6,7 (VWD) never receive a conclusive 
molecular diagnosis due to the unavailability of affordable genetic tests8. 
Hence treatment is compromised in some cases and the rapid identification of 
affected relatives may be impeded.	
 	
The aims of the ThromboGenomics project are to develop a multi-gene HTS 
platform for the diagnosis of BPDs, to deposit knowledge about novel 
pathogenic variants in a sustainable and freely available database and to 
leverage systematic Human Phenotype Ontology (HPO)-term based coding of 
patient phenotypes4 to improve our understanding of genotype-phenotype 
correlations in BPDs. To deliver the project to high scientific and ethical 
standards a global ThromboGenomics network of clinicians and researchers 
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with expertise in BPDs (supplemental Figure 1) was formed. Currently, the 
ThromboGenomics HTS platform can detect variants in the exonic fraction of 
63 BPD genes and many of their introns and untranslated regions (UTRs). 
Multiplexing allows the sequencing of DNA samples from 24 cases 
simultaneously. A custom capture is used instead of WES because it provides 
deeper coverage of the regions of interest for a given number of sequencing 
reads and allows a higher grade of multiplexing, thereby reducing the cost per 
patient diagnosed. 	
 	
Here we describe the technical performance of the ThromboGenomics 
platform and its accuracy for detecting causal variants in a curated set of 
transcripts in 63 BPD genes. We sequenced 300 samples (Figure 1), of which 
260 are unrelated, drawn from four groups of individuals having: diagnostic 
abnormalities on laboratory assays with previously ascertained pathogenic 
variants (known group; n=159), phenotypes strongly indicative of a particular 
disorder on the basis of laboratory abnormalities, but without knowledge of 
causal variants (suspected group; n=61), phenotypes that could not be 
matched to any known BPD because the laboratory assays were either 
normal or not diagnostic of an established disorder (uncertain group; n=76) 
and four samples from unaffected relatives.		
We developed a variant filtering procedure, assessed the platform’s 
reproducibility, used HPO-based prioritisation of candidate variants and 
reviewed the quality of the variant pathogenicity literature. Finally, we discuss 
the rules used by the multidisciplinary team (MDT) to review the sequencing 
results and generate reports.						
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METHODS	
Enrollment, gene and transcript selection, platform design and 
sequencing	
Individuals were enrolled in 13 different countries. The gene list was 
established through discussion with experts in BPDs and taking into account 
the quality of the evidence in the peer-reviewed literature supporting the claim 
to pathogenicity of variants in each gene, such as the number of unrelated 
individuals carrying the variants and functional validation of their effects in 
vitro. Transcripts were selected by experts for each gene, where available. 
The platform was designed to target all exonic and many intronic and UTRs of 
BPD genes. For further details on gene and transcript selection, platform 
design, sample preparation and sequencing, see supplemental Materials.		
Clinical bioinformatics 	
The reads in the de-multiplexed paired-end FASTQ files are processed as 
described in the supplemental Materials. Briefly, reads are aligned using 
BWA9 0.7.10. Then, SNVs and indels are called using GATK10 3.3 
HaplotypeCaller and CNVs are called using ExomeDepth11 1.1.5. As it is not 
possible to call inversions and complex structural rearrangements accurately 
with capture technology, they are not called.		
We infer gender using two statistics based on sequence reads aligned to well-
covered target regions (>95% of samples covered at 20X): the ratio between 
heterozygote and non-reference homozygote genotypes (het/hom) on the X 
chromosome sites and the ratio between the median coverage on X and the 
median coverage on the autosomes (aut/X). The het/hom ratio is computed 
using heterozygote SNVs with an allele depth between 0.3 and 0.7 to guard 
against errors.		
In order to estimate ethnic background, we project standardised genotypes 
onto the first two principal components obtained from the standardised 
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genotypes of 2,504 HapMap12 individuals sequenced by the 1000 Genomes 
project13. We use SNVs falling within well-covered target regions (>95% of 
samples covered at 20X), having a minor allele frequency (MAF) >0.02 in 
1000 Genomes and pruned with PLINK14 to ensure that r2<0.2 between pairs 
of SNVs. 		
We annotate SNVs and indels with their predicted impact against Ensembl 75, 
presence in HGMD 2015.2 and their MAFs in the ExAC 
(http://biorxiv.org/content/early/2015/10/30/030338) release 0.3 and 1000 
Genomes13 databases using SnpEff15 4.0. If variants are in HGMD16, then 
they are retained as long as their MAF in ExAC and in 1000 Genomes is 
<2.5%. Otherwise, variants must have a MAF <0.1% in ExAC and 1000 
Genomes, have <4 alternate alleles (as typically found in repetitive regions) 
and have a predicted moderate or high impact on translation of one of the 
ThromboGenomics transcripts according to SnpEff. In this latter group, we 
also allow through variants predicted to affect splice regions if they do not fail 
quality control in ExAC. Finally, any variants with a MAF >10% within the 
entirety of the ThromboGenomics data set are filtered out to remove potential 
systematic artefacts. The filtering criteria were informed by the variants in the 
known category of samples but applied universally.		
Our approach allows us to retain confidently called pathogenic variants which 
are regulatory or moderately common if they are already known to be 
pathogenic. Such variants include, for instance, the regulatory non-coding 
SNVs in RBM8A17,18 responsible for Thrombocytopenia Absent Radius (TAR) 
syndrome in the presence of a loss-of-function variant on the alternate 
haplotype, moderately common variants in VWF linked to reduced levels of 
the VWF protein19-21 and the F5 Leiden22 variant.				
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HPO-based prioritisation of variants	
We compute the semantic similarity S of a case’s HPO-coded phenotype to 
that of the HPO profiles of a BPD gene using the “best match average” 
metric23 and Lin's24 measure of similarity between terms: 	
	
where freq(t) is the frequency of term t in OMIM, anc(t) refers to union of term 
t and its ancestors in the HPO and (x1, x2) refers to the pair of sets of HPO 
terms being compared.		
Web application for variant assessment 	
Variant calls and phenotypes are visualised in the Sapientia web application 
(Congenica Inc., Cambridge, UK) during MDT meetings. Sapientia displays 
variant information such as predicted effect, MAFs in reference cohorts (e.g. 
ExAC, UK10K25) and links to external resources (e.g. HGMD, ClinVar, 
PubMed), as well as showing case data such as phenotype information in the 
form of HPO terms. The web application allows the MDT to annotate each 
variant with respect to its predicted contribution to the disease phenotype and 
its likely pathogenicity. Following international guidelines26, variants are 
marked as pathogenic (high impact or previously observed in at least four 
unrelated cases with a similar pathology), likely pathogenic (previously 
observed in <4 unrelated cases with a similar pathology) or as having 
unknown clinical significance. Considerations such as predicted impact (e.g. 
missense or loss of function) and conservation/pathogenicity scores are used 
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to inform how variants are categorised in the context of the observed 
phenotype. After deliberation the MDT produces a research report for the 
referring clinician including information about variants declared pathogenic or 
likely pathogenic but not usually about variants of unknown significance (VUS) 
(supplemental Figure 2). The typical overall turnaround time from sample 
submission to the production of a research report is less than 16 weeks. 		
RESULTS	
Coverage profile of the ThromboGenomics platform 
We have assessed the sequencing coverage profile of the ThromboGenomics 
platform using data from 300 samples. The mean exonic coverage along the 
58 autosomal genes (comprising 228,863 bp; supplemental Table 1) across 
samples from individuals of both sexes was on average 1,178 (range 123 to 
2,356) (Figure 2A). The mean fraction of exonic bases covered at 20X and 
50X was 0.993 and 0.989 respectively (Figure 2B). We have produced 
individualised coverage profiles for each gene on the platform showing that 
virtually all exonic regions of the ThromboGenomics transcripts are covered 
sufficiently for sensitive variant calling (supplemental File 1). The profile of 
ITGA2B encoding αIIb of the major platelet integrin is shown in Figure 2C as 
an example. A small number of short regions that may potentially suffer from 
low coverage are also highlighted in 19 genes (supplemental Table 2). 
Overall, 613 bp overlapping coding regions and only 44 out of the 8,294 
HGMD variants (0.53%) for the 63 genes were covered <20X in 95% of 
samples. Of these, 22 variants lie in exon 26 of VWF, which is perfectly 
homologous with part of the von Willebrand pseudogene 1 and 20 HGMD 
variants are in the highly GC-rich exon 2 of GP1BB. However, a change in the 
polymerase enzyme used in the library preparation improved the coverage on 
this (supplemental Figure 3) and other GC-rich regions such that all HGMD 
variants except for those on exon 26 of VWF could subsequently be called 
with confidence.		
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Sample identity assurance	
The MDT ensures that the gender (Figure 3A) and ethnic background (Figure 
3B), including admixture, inferred from the genotype data match the 
information provided by the clinical care team. Caucasoid individuals are over-
represented in the large collections of samples used for allele frequency 
based filtering. Consistent with this notion, individuals with non-European 
ancestry (particularly East Asian or African) tend to have more candidate 
variants (after filtering) than European or South Asian individuals (Figure 3B).		
Platform reproducibility	
The ThromboGenomics platform increases the total length of genome 
sequenced per case over 80-fold compared to a typical Sanger sequencing 
based test27, which raises the concern that a false diagnosis may arise from a 
spurious match between phenotype and a falsely called genotype. It is not 
feasible to verify all variants (including non-pathogenic variants) 
systematically using an alternative gold standard genotyping method and as 
such we cannot obtain a direct estimate of the false discovery rate (FDR) of 
the ThromboGenomics platform. However, any susceptibility towards spurious 
genotyping calls would likely manifest in low concordance rates between the 
variants obtained from different sequencing runs of the same sample. We 
thus assessed whether FDR is reasonably controlled by sequencing six DNA 
samples in two separate runs and comparing the candidate variants obtained 
between replicates. We found that every one of the 22 candidates called in 
either replicate was found in both replicates for all six pairs of samples. These 
results indicate that the library preparation, sequencing, variant calling and 
variant filtering altogether produce reproducible results and the risk of 
erroneous diagnoses due to falsely called variants is negligible.		
Overall, 75 samples had at least one of the CNV calls produced by the 
ExomeDepth algorithm comprising 47 deletions and 28 amplifications. To 
assess the dependability of these calls, we focused on the 29 heterozygous 
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autosomal deletions, found in 44 different samples, expected to be 
significantly depleted of heterozygous SNV calls under the hypothesis that the 
samples are truly haploid. In 82% of cases, no heterozygous SNVs spanned 
the putative deleted regions at all and the remainder contained between one 
and three heterozygous SNVs (supplemental Figure 4). Although some of 
these heterozygote calls may be due to read misalignment, a small proportion 
of CNV calls are likely the result of artifactual changes in coverage. 
Nevertheless, the highly significant overall depletion (p < 10-6), coupled with a 
proven sensitivity to identify pathogenic CNVs (see below), indicates that a 
reasonable balance between sensitivity and specificity is achieved by 
ExomeDepth in the difficult task of identifying CNVs. Given the symmetric 
modelling of deletions and amplifications, we expect similar performance in 
calling duplications. 	
Performance of variant calling and filtering	
The DNA from 300 individuals was sequenced and, across the entire dataset, 
20,039 variants were called, of which 520 SNVs, 47 indels and 75 CNVs 
remained after automated filtering. The mean number of variants per 
individual before filtering is 2,014.11 and this is reduced to 5.34 candidate 
causal variants (range 2 to 12) by the filtering procedure. Assuming there are 
two causal variants per individual and the filtering method classifies variants 
into candidates and non-candidates for pathogenicity in the worst possible 
way gives a lower bound for the specificity of variant filtration of 99.73%. On 
average, the 5.34 candidate variants consisted of 4.74 SNVs, 0.35 indels and 
0.25 CNVs (Figure 4). The CNV reads ratios clustered into groups 
corresponding to different zygosity (Figure 4D). 		
The candidate variants obtained from 159 individuals in the known group were 
used to assess the sensitivity of the platform. Members of this group had, or 
shared carrier status with, relatives who had one of 30 different BPDs. They 
included 19 with MYH9-related disorder, 11 with Glanzmann thrombasthenia 
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and 10 each with TAR syndrome, Wiskott–Aldrich syndrome (WAS), Platelet-
type VWD, Fibrinogen deficiency and Autosomal dominant thrombocytopenia. 
A further eight and six individuals had Gray platelet and Hermansky-Pudlak 
syndromes, respectively. The remaining 65 individuals in this group carried 
variants underlying other BPDs (Table 1). The previously known variants 
included 119 SNVs, 19 indels and seven large deletions in 37 different BPD 
genes. Of the 138 SNVs and indels, 102 (73.9%) were HGMD pathogenic 
variants and the remaining 36 variants were deemed to be causal by the 
clinician who submitted the sample and confirmed as likely pathogenic by the 
MDT. The longest indel detected in this group was called in DNA samples 
from two related patients diagnosed with platelet-type von Willebrand disease 
due to a heterozygous 27 bp in-frame deletion in GP1BA that removes amino 
acids 459–467. The large deletions varied in size, ranging from at least one 
exon to entire genes. After initial tuning of the bioinformatics pipeline, all 
causal variants across known BPD cases were identified after filtering and the 
genotypes matched the previously determined zygosity of the corresponding 
samples. Thus, the ThromboGenomics platform has an empirical sensitivity 
based on these 159 samples harbouring 145 causal variants (which do not 
include inversions) of 100% to detect known causal variants in BPD genes.		
Yield of the ThromboGenomics platform for cases with a suspected 
etiology	
We evaluated the utility of the platform in a clinical diagnostic setting by 
processing 61 samples from the suspected group, of which 52 are unrelated, 
using the same bioinformatics parameter settings as above. This group 
includes 28, 24 and nine cases with a coagulation factor, platelet or 
thrombotic disorder, respectively. The called variants were reviewed by the 
MDT in the context of the HPO terms annotated for each case29. In all but five 
of the 61 cases (91.8%; 90.4% for probands only), the MDT identified 
pathogenic or likely pathogenic variants that fully or partially explained the 
disease phenotype (Table 1). Overall, we identified 29 pathogenic and 28 
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likely pathogenic variants, comprising 44 SNVs, 13 indels and one duplication, 
of which 28 variants were novel and the remaining ones had previously been 
deposited in HGMD as BPD-causing variants.		
A noteworthy example concerns two cases from the same pedigree who were 
coded with the HPO terms “Impaired platelet aggregation”, “Spontaneous, 
recurrent epistaxis” and “Intramuscular hematoma” (Figure 5A). During 
analysis, all SNVs and indels that passed filtering were determined to be 
VUS. However, a duplication spanning the entirety of the PLAU gene was 
uncovered in both pedigree members (Figure 5B), hence a positive diagnosis 
was reached for Québec platelet disorder28. This example highlights the value 
of the ThromboGenomics platform because the standard laboratory marker of 
this condition, platelet aggregometry, is by no means conclusive.		
The unexplained cases included two with suspected Protein S deficiency, one 
with suspected Bernard-Soulier syndrome (BSS) and one with suspected type 
1 VWD. We have not yet been able to determine whether this was due to a 
lack of sensitivity (e.g. because of a complex rearrangement that cannot be 
detected by targeted sequencing) or because the cases had causative 
variants in relevant regulatory elements or in other trans-acting genes. In type 
1 VWD pathogenic variants are found in VWF in only ~50% of cases29 using 
Sanger sequencing. Alternatively the three cases may have an acquired BPD.		
We note that several samples in the suspected group were submitted after a 
negative result had been returned by Sanger sequencing in genes thought to 
harbour causal variants. In five cases, this result was overturned by the 
detection of causal variants by ThromboGenomics sequencing, which was 
subsequently confirmed in a second round of Sanger sequencing. A 
noteworthy example concerns two members in the same pedigree, initially 
diagnosed with alpha/delta-storage pool disease. The ThromboGenomics test 
results revealed a mutation in the RUNX1 gene changing the diagnosis to a 
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RUNX-1 associated thrombocytopenia with increased risk of acute myeloid 
leukemia. A further example illustrating how the ThromboGenomics platform 
can deliver more pertinent information than a standard single gene screening 
approach relates to a one-year old boy with thrombocytopenia, normal mean 
platelet volume and multiple hematomas after preterm birth without any other 
symptoms and having parents with normal platelet counts. Variants were 
found in both MYH9 and WAS that were coded by the MDT as ‘likely 
pathogenic’ and ‘VUS’, respectively. His mother carries a variant in WAS 
(located on the X chromosome) that was previously described for another 
male WAS patient30 while his father has a variant in MYH9 variant that has 
not been described previously. Further studies are required to determine 
whether the co-inheritance of the variants in MYH9 and WAS are causal of 
the lack of effective hemostasis. This example highlights the advantage of an 
HTS strategy that can identify potential disease-modifying factors, acting in 
trans, over a single gene analysis strategy. 	
Yield of the ThromboGenomics platform for cases with a highly 
uncertain etiology	
The third group of 76 uncertain cases, of which 62 are unrelated, is made up 
of a mixture of cases with unexplained BPDs that are not suggestive of a 
particular known pathology. This group mainly comprises patients with clinical 
bleeding problems, but having normal laboratory coagulation and platelet 
function tests, platelet storage pool disorder or patients who have had 
thrombotic events and low protein S levels though with a normal PROS1 
gene. We detected pathogenic or likely pathogenic variants in eight cases, 
corresponding to a sensitivity of 10.5% (9.68% for probands only). In two 
cases, the variants uncovered a contributory defect in a coagulation factor 
that explained the phenotype only partially (e.g. due to reduced levels that did 
not explain the bleeding). In the remaining six cases, defects explaining the 
phenotype in full were found in MYH9, PROC, PROS1, RUNX1, SERPINC1 
and TUBB1, including  a digenic molecular diagnosis involving a ‘likely 
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pathogenic’ variant in SERPINC1 and another in PROC, possibly explaining 
the thrombotic phenotype observed in this patient.		
Negative Sanger sequencing results were overturned in three cases within 
this group also, demonstrating that the ThromboGenomics platform can 
outperform Sanger sequencing in terms of sensitivity. However, the vast 
majority of cases in the uncertain group were given a negative result by the 
MDT, which underscores the need for further research into the molecular 
etiology of uncharacterised BPDs. 		
HPO-based prioritisation of candidate variants	
We transcribed phenotypes linked to the diseases associated with the 63 BPD 
genes into HPO terms (supplemental Table 3) and obtained HPO terms 
describing the phenotypes of a subset of the cases in our collection. To 
assess the potential utility of HPO methods for prioritising candidate variants, 
we compared the HPO terms for 109 cases who were previously determined 
to carry a pathogenic or likely pathogenic variant by the MDT to the HPO 
profiles linked to the genes in which they carried candidate variants. For 
example, a case with BSS from the suspected group was coded with six HPO 
terms and subsequently found to carry candidate variants in four genes. The 
homozygous variant in GP1BB, identified independently by the MDT as likely 
pathogenic, was chosen by the prioritisation algorithm as the top candidate 
because the HPO profile linked to GP1BB was more similar to the HPO profile 
of the case than the profiles of any of the other three genes in which the case 
had a candidate variant (Figure 6A). The overall results, shown in Figure 6B, 
indicate that in 85% (93/109) of cases, the correct gene, as identified by the 
MDT, scored the highest similarity to the case phenotype out of all the 
candidate variants (p <10-6). Whenever the top-ranked gene did not 
correspond to the MDT-designated gene, the difference tended to be smaller 
than when there was concordance (supplemental Figure 5). Thus, HPO-
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based prioritisation offers a promising route towards streamlining the review 
process by MDTs. 		
On the reliability of the variant pathogenicity literature	
Presence of a candidate variant in HGMD is often considered a strong 
indicator of pathogenicity subject to a phenotype match between the disease 
linked with the variant, the patient’s phenotype and a consistent mode of 
inheritance (Table 1). The variants in HGMD belong to different classes 
depending on whether they are considered disease-causing mutations 
(labelled “DM” if definitive and “DM?” if the curator had reservations), disease-
associated polymorphisms or other types of variants. The variant with dbSNP 
ID rs139428292 in the 5′ UTR of the RBM8A gene is causal of TAR if the 
alternate RBM8A allele harbours a loss of function variant. This UTR variant is 
listed in HGMD as an “in vitro or in vivo functional polymorphism” instead of 
as a cause of TAR. The Factor V Leiden variant rs6025 is listed as a 
“disease-associated polymorphism with additional supporting functional 
evidence”. Consequently, we use HGMD variants in all classes in our MDT 
analysis.	
 	
The vast majority of HGMD variants in the 63 BPD genes (7,320 out of 8,294) 
have a MAF that is either zero or undetermined in the 60,706 controls from 
the ExAC database. However, 140 variants have a MAF >1/1,000, of which 
69 are listed as disease-causing (Figure 7). We reviewed the literature for 
these 140 variants and concluded that there is sufficient evidence supporting 
a claim to penetrant pathogenicity for only seven variants (supplemental Table 
4). Historically, assignment of pathogenicity has sometimes been based on 
publications of variants in small pedigrees without large numbers of control 
samples or supporting biochemical or cell biology data, such as expression 
studies. We considered such variants to be of unproven pathogenicity in 
accordance with current standards. The genes F531,32, F833,34, F1135, 
PROS135, FLNA36, THBD37,38, VWF39 and WAS40 had the highest rates of 
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these doubtfully  annotated variants, with counts ranging between three (F5, 
F11, THBD and WAS) and 17 (VWF). By way of example, for MYH9, a 
methionine1651threonine is classified in HGMD as DM. However, the MAF is 
1.29 in 1,000 in ExAC and therefore it cannot underlie a high-penetrance 
autosomal dominant disorder. Indeed, the authors41 reporting this mutation 
observed it in a single pedigree in which two cases and no unaffected 
relatives were screened and decided that its absence in a mere 45 control 
samples was sufficient to infer causality for the child’s Alport syndrome and 
the mother’s hearing loss. Regarding F8, the doubtful DM variants are 
typically in the B-domain and may influence F8 levels but are unlikely to be 
causal of haemophilia A. With the above considerations in mind, the 
ThromboGenomics MDT critically assesses the evidence supporting claims to 
pathogenicity of each candidate variant in the context of allele frequencies in 
the major variant databases, even for variants that are present in HGMD.		
DISCUSSION	
We have described a comprehensive and cost-effective strategy for the 
diagnosis of BPDs. The HTS platform and accompanying processing and 
filtering methods have high sensitivity (100% based on 159 samples) to detect 
and shortlist causal variants (SNVs, indels and CNVs) when the variants are 
known to be in a BPD gene on the ThromboGenomics platform. When the 
phenotype is strongly indicative of the presence of a particular disease 
etiology but the variants are unknown, sensitivity remains high (>90% based 
on 61 samples). Our variant filtering approach has high specificity (>99.5%) 
as it greatly reduces the number of candidates that require consideration by 
the MDT and, as we have shown, HPO-based prioritisation methods may 
reduce the burden on MDTs even further by highlighting pathogenic or likely 
pathogenic variants as the top candidate in about 85% of cases. Sanger 
results have been overturned by results obtained by HTS and the CNV-calling 
pipeline compares favourably with other assays such as multiplex ligation-
dependent probe amplification (MLPA42). In order to facilitate interpretation of 
19			
the genetic data, variants are annotated against clinically relevant transcripts, 
which were selected by experts and deposited in the LRG public reference 
database for use by clinical genetics laboratories.		
At MDT meetings, we assume that truly pathogenic variants in BPD genes 
generally have a MAF <1/1,000 for autosomal recessive disorders and are 
likely much rarer for X-linked and dominant disorders. Decisions used to 
reach a diagnosis are guided by MAFs in major reference databases and data 
extracted from the literature, which has been deposited in the HGMD 
database. We have shown that variants in all HGMD classes must be 
considered as potentially pertinent yet 140 variants have a MAF in ExAC 
>1/1,000, only four of which are established as pathogenic and penetrant, 
while the others either exert small effects or have uncertain clinical 
significance. The VWF gene, for example, which has an open reading frame 
length in the top 1% of the genome-wide distribution, has 17 variants labelled 
as pathogenic or likely pathogenic with a MAF>1/1000 in ExAC. Reasons for 
this include low control sample numbers and an over-reliance on in vitro 
function tests, pathogenicity prediction algorithms and crystallography data. 
Given the good performance of the sequencing, variant calling and filtering 
procedures, the specificity of the ThromboGenomics test as a whole must be 
determined in large part by the rate at which non-pertinent variants are falsely 
declared pathogenic. Although we have not been able to measure specificity 
directly, careful adjudication of the results by the MDT along the lines we have 
discussed should ensure that false positive reports are rare.		
Overall, we have identified 204 distinct pathogenic or likely pathogenic 
variants, of which 8 are CNVs and 64 are absent from HGMD. The 73 cases 
for whom no conclusive diagnosis could be reached will be considered for 
inclusion in the 100,000 Genomes projects to be analysed by WGS.  
Aggregating these cases with the current set of approximately 1,000 BPD 
cases already analysed by WES or WGS will improve power to identify novel 
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causes of BPDs. Meanwhile, the on-going work of the ThromboGenomics 
project will improve the catalogues of pathogenic variants for known BPD 
genes to aid future diagnoses. However, as the ThromboGenomics platform 
cannot identify inversions and ~45% of severe Haemophilia A cases are due 
to inversions, a simple PCR-based test can be performed to exclude them 
prior to HTS.		
The clinical importance of an affordable HTS test to patient care should not be 
underestimated. For example, in the UK, sequencing of only HPS1 and HPS3 
genes for patients with a suspected diagnosis of HPS is reimbursed. 
However, the precise genetic diagnosis of HPS cases is clinically relevant 
because those with causal variants in the HPS1, 2 and 4 genes may develop 
lung fibrosis, which requires monitoring, whilst this is not the case for variants 
in the remaining six HPS genes. Furthermore, the identification of variants in 
genes like RUNX1 and ETV6, associated with heightened risk of malignancy, 
would allow patients at risk to benefit from surveillance. 	
During the validation period of the ThromboGenomics platform, 13 new BPD 
genes have been reported and these 13 and a further 25 genes 
(supplemental Table 5) for cerebral small vessel disease, hereditary 
haemorrhagic telangiectasia, arteriovenous malformations and pulmonary 
arterial hypertension have been included in the next version of the 
ThromboGenomics platform. For the version reported in this manuscript we 
used one capture reaction for every two samples and multiplexed 24 samples 
on a single HiSeq lane. With improved reagents and protocols for multiplexing 
and the substantial increase in the number of reads per HiSeq lane the 
capture of at least 4 samples per reaction will be feasible in the near future, 
whilst maintaining excellent coverage. As a result of this modification the cost 
per sample tested can be reduced further.	
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HTS-based tests are rapidly becoming routine in clinical practice and the 
ThromboGenomics platform is an example of this transformation. The aim is 
for the ThromboGenomics test, available through 
www.thrombogenomics.org.uk, to become the first choice for haemostasis 
and thrombosis physicians and haematologists requiring a molecular 
diagnosis for BPD cases. This platform and the underpinning principle of 
freely accessible expert knowledge about genes, transcripts and causal 
variants and the approach of using HPO terms for coding phenotype can be 
used by reference laboratories to reduce the diagnostic delay in reaching a 
conclusive molecular diagnosis for BPD patients. We believe that, by 
facilitating provision of a definitive diagnosis, our platform will bring substantial 
benefits to the estimated 2 million BPD cases worldwide. 	
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Tables		
Table 1. The 63 BPD genes present in the ThromboGenomics platform. 
BPDs targeted by the ThromboGenomics platform, grouped by disorder type 
and gene. For each gene and disease, the main mode of inheritance (MOI — 
AR: autosomal recessive; AD: autosomal dominant. XR: X-linked recessive) 
and the number of individuals in the known, suspected and uncertain 
categories found to carry a pathogenic variant by the ThromboGenomics 
platform are shown, with sub-totals for each set of disorders shown in 
brackets. One patient in the uncertain group is shown on two rows because 
she was given a digenic molecular diagnosis involving a likely pathogenic 
variant in SERPINC1 and another in PROC. GP1BA appears twice because 
variants therein may be implicated in disorders listed on two separate rows 
(Bernard-Soulier syndrome and platelet-type von Willebrand disease). Note 
that gain-of-function variants in coagulation factor genes F2, F5, FGA, FGB, 
FGG may be involved in thrombotic disorders but these are not shown, with 
the exception of Factor V Leiden.  	
Coagulation Factor Disorders	 Genes	 Main MOI	 known	(41)	 suspected (26)	 uncertain (2)	
Combined V and VIII deficiency	 LMAN1; MCFD2	 AR;  AR	  	  	  	
Factor V deficiency  
and Factor V Leiden	 F5	 AR	 4	 5	  1	
Factor VII deficiency	 F7	 AR	 4	 5	  	
Factor X deficiency	 F10	 AR	 2	 	  	
Factor XI deficiency	 F11	 AR	 2	  1	  1	
Factor XIII deficiency	 F13A1; F13B	 AR;  AR	 2; 0	 1; 0	  	
Fibrinogen deficiency	 FGA; FGB; FGG	 AD; AR;  AR	 7; 1; 2	 3; 0; 0	  	
Fletcher factor deficiency	 KLKB1	 AR	  	  	  	
Haemophilia A	 F8	 XR	 5	 3	  0	
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Haemophilia B	 F9	 XR	 5	  	  	
Multiple coagulation factor 
deficiency type 1	 GGCX	 AR	  	  	  	
Multiple coagulation factor 
deficiency type 2	 VKORC1	 AR	  	  	  	
Plasminogen activator inhibitor 1 
deficiency	 SERPINE1	 AR	  	  	  	
Plasminogen deficiency	 PLG	 AR	  	 1	  	
Prothrombin deficiency	 F2	 AR	 2	 4	  	
Kininogen deficiency	 KNG1	 AR	  	  	  	
von Willebrand disease	 VWF	 AD	 5	 3	  		
Platelet Disorders	 Genes	 Main MOI	 known	(110)	 suspected (23)	 uncertain	(4)	
ADP receptor defect	 P2RY12	 AR	 1	  	  	
Amegakaryocytic thrombocytopenia 
with radioulnar synostosis	 HOXA11	 AD	  	  	  	
Autosomal dominant 
thrombocytopenia	 ANKRD26; CYCS; TUBB1	 AD;  AD; AD	 1; 4; 5	 0; 0; 1	  0; 0; 1	
Bernard-Soulier syndrome	 GP1BA; GP1BB; GP9	 AR;  AR; AR	 3; 1; 0	 0; 1; 0	  	
Bleeding diathesis due to 
glycoprotein VI deficiency	 GP6	 AR	 1	  	  	
Chediak-Higashi syndrome	 LYST	 AR	  	  	  	
Congenital amegakaryocytic 
thrombocytopenia (CAMT)	 MPL	 AR	 5	  	  	
Cyclic thrombocytopenia and 
thrombocythemia 1	 THPO	 AD	  	  	  	
Deficiency of phospholipase A2, 
group IVA	 PLA2G4A	 AR	  	  	  	
Dense granule abnormalities	 NBEA	 AD	  	  	  	
Familial platelet disorder with 
predisposition to AML	 RUNX1	 AD	 2	  	  2	
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Filamin A-related disorders FLNA  XR 1     
Ghosal syndrome	 TBXAS1	 AR	  	  	  	
Glanzmann thrombasthenia	 ITGA2B; ITGB3	 AR; AR	 5; 6	 4; 0	  	
Gray platelet syndrome	 NBEAL2	 AR	 8	 	  	
Hermansky-Pudlak syndrome	 HPS1; AP3B1; HPS3; HPS4; HPS5; HPS6; 
DTNBP1; 
BLOC1S3	
AR; AR; 
AR; AR; 
AR; AR; 
AR; AR	 1; 0; 2; 0; 0; 2; 1; 0	 4; 0; 0; 0; 2; 3; 0; 0	  	
May-Hegglin and other MYH9-
related disorders	 MYH9	 AD	 19	 4	  1	
Paris-Trousseau thrombocytopenia 
and Jacobson syndrome	 FLI1	 AD	  	  	  	
Platelet-type von Willebrand 
disease	 GP1BA	 AD	 10	  	  	
Québec platelet disorder	 PLAU	 AD	  	  2	  	
Thrombocytopenia absent radius 
(TAR) syndrome	 RBM8A	 AR	 10	 	  	
Thromboxane A2 receptor defect	 TBXA2R	 AR	 2	  1	  	
Wiskott-Aldrich syndrome	 WAS	 XR	 16	 1	  	
X-linked thrombocytopenia with 
dyserythropoiesis	 GATA1	 XR	 4	  	  		
Thrombotic Disorders	 Genes	 Main MOI	 known	(8)	 suspected	(7)	 uncertain	(3)	
Antithrombin deficiency	 SERPINC1	 AR	 4	  	  1	
Heparin co-factor 2 deficiency	 SERPIND1	 AD	  	  	  	
Histidine-rich glycoprotein deficiency	 HRG	 AD	  	  	  	
Protein C deficiency	 PROC	 AR	 2	 3	  1	
Protein S deficiency	 PROS1	 AR	 2	 4	  1	
Thrombomodulin deficiency	 THBD	 AD	  	  	  	
Tissue plasminogen activator 
deficiency	 PLAT	 AD	  	  	  	
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Figure  Legends		
Figure 1. Breakdown of the 300 samples sequenced with the 
ThromboGenomics platform. The width of each box is proportional to the 
number of individuals it represents. The four main categories are shown as 
labels in italics. The shaded area in each box reflects the proportion of 
samples in which pathogenic or likely pathogenic variants were identified with 
the ThromboGenomics platform. Note that the mother of a haemophilia A 
patient from the suspected group appears in shading in the box representing 
the unaffected group.		
Figure 2.	 Technical evaluation of the ThromboGenomics platform. A. 
Histogram of mean autosomal target coverage for 321 samples. B. Mean 
fraction of exonic (solid black) bases and HGMD variants (dashed red) 
covered at least at 0X, 1X, …, 50X. C. Coverage profile for the ITGA2B gene.		
Figure 3.	Sample identity assurance. A. The het/hom ratio versus the aut/X 
ratio is used to infer the gender of each individual. One sample from a male 
individual with an abnormally high aut/X ratio was substantially more 
degraded than all others. B. A scatterplot of the first two principal components 
derived from the 1000 Genomes genotypes, with individuals coloured by 
major population and projected ThromboGenomics individuals shown as black 
circles if they have fewer than seven candidate variants and triangles if they 
have at least seven candidate variants. For clarity, admixed American 
HapMap individuals are not shown. There is a lower density of 
ThromboGenomics individuals with African or East Asian ancestry but they all 
have at least seven variants, while approximately 80% of ThromboGenomics 
individuals with European ancestry have fewer than seven variants.		
Figure 4.	Candidate variants per sample. A-C. Bar plots of the number of 
candidate SNVs, indels and CNVs per individual. D. Scatterplot of the Bayes 
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Factor versus the observed over expected reads ratio for each CNV called by 
ExomeDepth and the thresholds distinguishing different levels of changes in 
zygosity. Note that the number of called CNVs is slightly biased upwards 
relative to the number of true CNVs because a single underlying CNV can 
sometimes be coded as multiple adjacent calls by the ExomeDepth algorithm. 
The fraction of CNVs surviving filtering is slightly elevated relative to the 
fraction of indels because we include calls with a Bayes factor down to 4.5 for 
maximum sensitivity and because they do not undergo any external cohort-
based frequency filtering.		
Figure 5.	 Case study.	 A. Human Phenotype Ontology (HPO) encoded 
phenotype of a case in the suspected category, visualised as a graph using 
the hpoPlot package. Note that “Abnormality of leukocytes” is also an 
“Abnormality of the immune system” (not shown). B. The ratio between 
observed and expected read depth over the PLAU gene for the case is shown 
in red and superimposed over the 95% confidence interval shown as a grey 
shaded area. In the lower panel the central position of each exon of the PLAU 
gene is shown as a vertical bar and the gene coordinates are provided on the 
horizontal axis. The data indicate that the case carries an additional copy of 
the PLAU gene (Bayes factor = 145), which is compatible with a diagnosis of 
suspected Québec platelet syndrome.		
Figure 6.	 HPO-based prioritisation. A. HPO profile of a case with BSS 
encoded as a graph. Note atypical presence of hearing impairment, which is 
likely unrelated to the BSS. The plot beneath the graph shows the similarities 
between the patient profile and each gene in which the case has a candidate 
variant. The profile of GP1BB is the most similar out of the four genes with 
candidate variants. B.  For each of the 109 HPO-coded cases for which a 
causative variant was assigned by the MDT, the similarity is shown between 
the case profile and the profiles of the genes in which the case has a 
candidate variant. The similarity to the gene containing the variant(s) 
31			
determined to be pathogenic or likely pathogenic in each case is shown as a 
red circle and the similarity to other genes containing variants of unknown 
significance are shown as gray dashes. Case index 1 corresponds to the BSS 
case shown in A.		
Figure 7.	HGMD variants and corresponding minor allele frequencies in 
ExAC. A. Truncated log-scale barplot showing the number of HGMD variants 
by HGMD phenotype. B. Log-scale barplot showing the number of HGMD 
variants binned by MAF in ExAC. C. Histogram of the 140 variants in BPD 
genes with a MAF in ExAC exceeding 1/1,000 (i.e. belonging to the blue bins 
in panel B) broken down by HGMD phenotype. The individual Phred-scaled 
MAFs of the variants (i.e. such that 30 corresponds to 1/1,000 and 20 to 
1/100) are superimposed on the histogram and coloured by whether they are 
classified as disease causing (DM and DM? categories).		 	
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